Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297: 353-356. 10.1126/science.1072994.
CAS
PubMed
Google Scholar
Selkoe DJ: Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol. 1994, 53: 438-447. 10.1097/00005072-199409000-00003.
CAS
PubMed
Google Scholar
Selkoe DJ: Alzheimer's disease is a synaptic failure. Science. 2002, 298: 789-791. 10.1126/science.1074069.
CAS
PubMed
Google Scholar
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999, 400: 173-177. 10.1038/22124.
CAS
PubMed
Google Scholar
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001, 98: 8850-8855. 10.1073/pnas.151261398.
PubMed Central
CAS
PubMed
Google Scholar
Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D: Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003, 23: 3745-3751.
CAS
PubMed
Google Scholar
Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM: Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2006, 281: 1599-1604. 10.1074/jbc.M507892200.
CAS
PubMed
Google Scholar
Brody DL, Holtzman DM: Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008, 31: 175-193. 10.1146/annurev.neuro.31.060407.125529.
PubMed Central
CAS
PubMed
Google Scholar
Schenk D, Hagen M, Seubert P: Current progress in beta-amyloid immunotherapy. Curr Opin Immunol. 2004, 16: 599-606. 10.1016/j.coi.2004.07.012.
CAS
PubMed
Google Scholar
Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, Kounnas MZ, Lamb BT, Barten D, Felsenstein K, McDonald I, Srinivasan K, Munoz B, Wagner SL: Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol. 2005, 69: 689-698. 10.1016/j.bcp.2004.11.015.
CAS
PubMed
Google Scholar
Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, Polson CT, Wang J, Roberts SB, Hendrick JP, Anderson JJ, Loy JK, Denton R, Verdoorn TA, Smith DW, Felsenstein KM: Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther. 2005, 312: 635-643. 10.1124/jpet.104.075408.
CAS
PubMed
Google Scholar
Best JD, Jay MT, Otu F, Churcher I, Reilly M, Morentin-Gutierrez P, Pattison C, Harrison T, Shearman MS, Atack JR: In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) in the rat. J Pharmacol Exp Ther. 2006, 317: 786-790. 10.1124/jpet.105.100271.
CAS
PubMed
Google Scholar
Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, Lewis HD, Pattison C, Reilly M, Harrison T, Shearman MS, Williamson TL, Atack JR: Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-ox o-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther. 2005, 313: 902-908. 10.1124/jpet.104.081174.
CAS
PubMed
Google Scholar
Best JD, Smith DW, Reilly MA, O'Donnell R, Lewis HD, Ellis S, Wilkie N, Rosahl TW, Laroque PA, Boussiquet-Leroux C, Churcher I, Atack JR, Harrison T, Shearman MS: The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther. 2007, 320: 552-558. 10.1124/jpet.106.114330.
CAS
PubMed
Google Scholar
Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J, Yang S, et al: Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001, 76: 173-181. 10.1046/j.1471-4159.2001.00012.x.
CAS
PubMed
Google Scholar
Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, Merchant KM: The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther. 2003, 305: 864-871. 10.1124/jpet.102.048280.
CAS
PubMed
Google Scholar
Lanz TA, Hosley JD, Adams WJ, Merchant KM: Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo -6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther. 2004, 309: 49-55. 10.1124/jpet.103.060715.
CAS
PubMed
Google Scholar
Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, Fei Q, Ebbinghaus CF, Chen YL, Spracklin DK, Tate B, Geoghegan KF, Lau LF, Auperin DD, Schachter JB: Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther. 2006, 319: 924-933. 10.1124/jpet.106.110700.
CAS
PubMed
Google Scholar
Garcia-Alloza M, Subramanian M, Thyssen D, Borrelli LA, Fauq A, Das P, Golde TE, Hyman BT, Bacskai BJ: Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener. 2009, 4: 19-10.1186/1750-1326-4-19.
PubMed Central
PubMed
Google Scholar
May PC, Altstiel LD, Bender MH, Boggs LN, Calligaro DO, Fuson KS, Gitter BD, Hyslop PA, Jordan WH, Li WY, Mabry TE, Mark RJ, Ni B, Nissen JS, Porter WJ, Sorgen SG, Su Y, Audia JE, Dovey HF, Games D, John V, Freedman SB, Guido T, Johnson-Wood KL, Kahn K, Latimer LH, Lieberburg IM, Seubert PA, Soriano F, Thorsett ED, et al: Marked reduction of Aβ accumulation and β-amyloid plaque pathology in mice upon chronic treatment with a functional gamma-secretase inhibitor. Soc for Neurosci Abstr. 2001, 27: 687.1-
Google Scholar
Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, Stoeckli M, Rueeger H, Neumann U, Staufenbiel M: Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther. 2008, 327: 411-424. 10.1124/jpet.108.140327.
CAS
PubMed
Google Scholar
Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM: Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009, 29: 10706-10714. 10.1523/JNEUROSCI.2637-09.2009.
PubMed Central
CAS
PubMed
Google Scholar
Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL: Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2005, 25: 8898-8902. 10.1523/JNEUROSCI.2693-05.2005.
CAS
PubMed
Google Scholar
Townsend M, Qu Y, Gray A, Wu Z, Seto T, Hutton M, Shearman MS, Middleton RE: Oral treatment with a gamma-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's Disease. J Pharmacol Exp Ther. 2010, 333: 110-119. 10.1124/jpet.109.163691.
CAS
PubMed
Google Scholar
Churcher I, Beher D: Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease. Curr Pharm Des. 2005, 11: 3363-3382. 10.2174/138161205774370771.
CAS
PubMed
Google Scholar
Garofalo AW: Patents targeting γ-secretase inhibition and modulation for the treatment of Alzheimer's disease: 2004 - 2008. Expert Opin Ther Patents. 2008, 18: 693-703. 10.1517/13543776.18.7.693.
CAS
Google Scholar
Imbimbo BP: Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem. 2008, 8: 54-61. 10.2174/156802608783334015.
CAS
PubMed
Google Scholar
Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ: Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004, 82: 341-358. 10.1093/toxsci/kfh254.
CAS
PubMed
Google Scholar
Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, Ryan TP: Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem. 2003, 278: 46107-46116. 10.1074/jbc.M307757200.
CAS
PubMed
Google Scholar
Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM: Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004, 279: 12876-12882. 10.1074/jbc.M311652200.
CAS
PubMed
Google Scholar
Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008, 65: 1031-1038. 10.1001/archneur.65.8.1031.
PubMed Central
PubMed
Google Scholar
Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC: Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005, 28: 126-132. 10.1097/01.wnf.0000167360.27670.29.
CAS
PubMed
Google Scholar
Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC: Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006, 66: 602-604. 10.1212/01.WNL.0000198762.41312.E1.
CAS
PubMed
Google Scholar
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials. [http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794]
Jensen J, Pedersen EE, Galante P, Hald J, Heller RS, Ishibashi M, Kageyama R, Guillemot F, Serup P, Madsen OD: Control of endodermal endocrine development by Hes-1. Nat Genet. 2000, 24: 36-44. 10.1038/71657.
CAS
PubMed
Google Scholar
Jenny M, Uhl C, Roche C, Duluc I, Guillermin V, Guillemot F, Jensen J, Kedinger M, Gradwohl G: Neurogenin3 is differentially required for endocrine cell fate specification in the intestinal and gastric epithelium. EMBO J. 2002, 21: 6338-6347. 10.1093/emboj/cdf649.
PubMed Central
CAS
PubMed
Google Scholar
Lee CS, Perreault N, Brestelli JE, Kaestner KH: Neurogenin 3 is essential for the proper specification of gastric enteroendocrine cells and the maintenance of gastric epithelial cell identity. Genes Dev. 2002, 16: 1488-1497. 10.1101/gad.985002.
PubMed Central
CAS
PubMed
Google Scholar
Yang Q, Bermingham NA, Finegold MJ, Zoghbi HY: Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science. 2001, 294: 2155-2158. 10.1126/science.1065718.
CAS
PubMed
Google Scholar
Stanger BZ, Datar R, Murtaugh LC, Melton DA: Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci USA. 2005, 102: 12443-12448. 10.1073/pnas.0505690102.
PubMed Central
CAS
PubMed
Google Scholar
Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H, Linn M, Flohr A, Jakob-Rotne R, Jacobsen H, Glenn K, Heimbrook D, Boylan JF: Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res. 2009, 69: 7672-7680. 10.1158/0008-5472.CAN-09-1843.
CAS
PubMed
Google Scholar
Hyde LA, McHugh NA, Chen J, Zhang Q, Manfra D, Nomeir AA, Josien H, Bara T, Clader JW, Zhang L, Parker EM, Higgins GA: Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo -6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther. 2006, 319: 1133-1143. 10.1124/jpet.106.111716.
CAS
PubMed
Google Scholar
Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I, Meijerink J, Aifantis I, Basso G, Cordon-Cardo C, Ai W, Ferrando A: Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009, 15: 50-58. 10.1038/nm.1900.
PubMed Central
CAS
PubMed
Google Scholar
Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE: NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003, 112: 440-449.
PubMed Central
CAS
PubMed
Google Scholar
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001, 414: 212-216. 10.1038/35102591.
CAS
PubMed
Google Scholar
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH: Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem. 2003, 278: 31831-31837. 10.1074/jbc.M303592200.
CAS
PubMed
Google Scholar
Olson RE, Albright CF: Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem. 2008, 8: 17-33. 10.2174/156802608783334088.
CAS
PubMed
Google Scholar
Cole DC, Stock JR, Kreft AF, Antane M, Aschmies SH, Atchison KP, Casebier DS, Comery TA, Diamantidis G, Ellingboe JW, Harrison BL, Hu Y, Jin M, Kubrak DM, Lu P, Mann CW, Martone RL, Moore WJ, Oganesian A, Riddell DR, Sonnenberg-Reines J, Sun SC, Wagner E, Wang Z, Woller KR, Xu Z, Zhou H, Jacobsen JS: (S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor. Bioorg Med Chem Lett. 2009, 19: 926-929. 10.1016/j.bmcl.2008.11.116.
CAS
PubMed
Google Scholar
Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, et al: Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009, 331: 598-608. 10.1124/jpet.109.152975.
CAS
PubMed
Google Scholar
Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH, Tarenflurbil Phase 3 Study G: Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009, 302: 2557-2564. 10.1001/jama.2009.1866.
PubMed Central
CAS
PubMed
Google Scholar
Hendrix SB, Wilcock GK: What we have learned from the Myriad trials. J Nutr Health Aging. 2009, 13: 362-364. 10.1007/s12603-009-0044-7.
CAS
PubMed
Google Scholar
Eisai to Resume Clinical Study to Evaluate E2012 as a Potential Next Generation Alzheimer's Disease Treatment. [http://www.eisai.co.jp/enews/enews200818.html]
Pissarnitski D: Advances in gamma-secretase modulation. Curr Opin Drug Discov Devel. 2007, 10: 392-402.
CAS
PubMed
Google Scholar
Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M: CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol. 2009, 156: 982-993. 10.1111/j.1476-5381.2008.00097.x.
PubMed Central
CAS
PubMed
Google Scholar
Shelton CC, Zhu L, Chau D, Yang L, Wang R, Djaballah H, Zheng H, Li YM: Modulation of gamma-secretase specificity using small molecule allosteric inhibitors. Proc Natl Acad Sci USA. 2009, 106: 20228-20233. 10.1073/pnas.0910757106.
PubMed Central
CAS
PubMed
Google Scholar
Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynet D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, Mobley WC, Li YM, Sisodia SS, Tanzi RE, Wagner SL: Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron. 2010, 67: 769-780. 10.1016/j.neuron.2010.08.018.
PubMed Central
CAS
PubMed
Google Scholar
Fraering PC, Ye W, LaVoie MJ, Ostaszewski BL, Selkoe DJ, Wolfe MS: gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem. 2005, 280: 41987-41996. 10.1074/jbc.M501368200.
PubMed Central
CAS
PubMed
Google Scholar
Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, Bornmann WG, Clarkson B, Xu H, Greengard P: Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci USA. 2003, 100: 12444-12449. 10.1073/pnas.1534745100.
PubMed Central
CAS
PubMed
Google Scholar
He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, Bettayeb K, Flajolet M, Gorelick F, Wennogle LP, Greengard P: Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature. 2010, 467: 95-98. 10.1038/nature09325.
PubMed Central
CAS
PubMed
Google Scholar
Zhao B, Yu M, Neitzel M, Marugg J, Jagodzinski J, Lee M, Hu K, Schenk D, Yednock T, Basi G: Identification of gamma-secretase inhibitor potency determinants on presenilin. J Biol Chem. 2008, 283: 2927-2938. 10.1074/jbc.M708870200.
CAS
PubMed
Google Scholar
Mattson MN, Neitzel ML, Quincy DA, Semko CM, Garofalo AW, Keim PS, Konradi AW, Pleiss MA, Sham HL, Brigham EF, Goldbach EG, Zhang H, Sauer JM, Basi GS: Discovery of sulfonamide-pyrazole gamma-secretase inhibitors. Bioorg Med Chem Lett. 2010, 20: 2148-2150. 10.1016/j.bmcl.2010.02.050.
CAS
PubMed
Google Scholar
Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V: Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999, 402: 537-540. 10.1038/990114.
CAS
PubMed
Google Scholar
Kimberly WT, Esler WP, Ye W, Ostaszewski BL, Gao J, Diehl T, Selkoe DJ, Wolfe MS: Notch and the amyloid precursor protein are cleaved by similar gamma-secretase(s). Biochemistry. 2003, 42: 137-144. 10.1021/bi026888g.
CAS
PubMed
Google Scholar
Hsieh JJ, Henkel T, Salmon P, Robey E, Peterson MG, Hayward SD: Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol. 1996, 16: 952-959.
PubMed Central
CAS
PubMed
Google Scholar
Shawber C, Nofziger D, Hsieh JJ, Lindsell C, Bogler O, Hayward D, Weinmaster G: Notch signaling inhibits muscle cell differentiation through a CBF1-independent pathway. Development. 1996, 122: 3765-3773.
CAS
PubMed
Google Scholar
Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L: Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997, 94: 1550-1555. 10.1073/pnas.94.4.1550.
PubMed Central
CAS
PubMed
Google Scholar
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995, 373: 523-527. 10.1038/373523a0.
CAS
PubMed
Google Scholar
Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ: Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992, 360: 672-674. 10.1038/360672a0.
CAS
PubMed
Google Scholar
Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ, et al: Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature. 1993, 361: 260-263. 10.1038/361260a0.
CAS
PubMed
Google Scholar
Beher D, Fricker M, Nadin A, Clarke EE, Wrigley JD, Li YM, Culvenor JG, Masters CL, Harrison T, Shearman MS: In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand. Biochemistry. 2003, 42: 8133-8142. 10.1021/bi034045z.
CAS
PubMed
Google Scholar
Fraering PC, LaVoie MJ, Ye W, Ostaszewski BL, Kimberly WT, Selkoe DJ, Wolfe MS: Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry. 2004, 43: 323-333. 10.1021/bi035748j.
CAS
PubMed
Google Scholar
Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israel A: A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell. 2000, 5: 207-216. 10.1016/S1097-2765(00)80417-7.
CAS
PubMed
Google Scholar
Fortini ME: Notch and presenilin: a proteolytic mechanism emerges. Curr Opin Cell Biol. 2001, 13: 627-634. 10.1016/S0955-0674(00)00261-1.
CAS
PubMed
Google Scholar
Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, Ray WJ, Kopan R: A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell. 2000, 5: 197-206. 10.1016/S1097-2765(00)80416-5.
CAS
PubMed
Google Scholar
Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N, Matsuoka Y: BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J Neurochem. 2006, 99: 1555-1563. 10.1111/j.1471-4159.2006.04178.x.
CAS
PubMed
Google Scholar
van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H: Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005, 435: 959-963. 10.1038/nature03659.
CAS
PubMed
Google Scholar
Schroeter S, Brigham EF, Motter R, Nishioka C, Guido T, Kahn K, Kholodenko D, Tanaka P, Soriano F, Quinn KP, Goldbach E, Games D, Ness D: APP-selective gamma secretase inhibitor ELND006 effects on brain parenchymal and vascular amyloid beta in the PDAPP mouse model of Alzheimer's Disease (P3-321). Supplement to Alzheimer's and Dementia; International Conference on Alzheimer's Disease, Honolulu, Hawaii. 2010, Alzheimer's Association, S546-
Google Scholar
Berezovska O, Jack C, McLean P, Aster JC, Hicks C, Xia W, Wolfe MS, Kimberly WT, Weinmaster G, Selkoe DJ, Hyman BT: Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling. J Neurochem. 2000, 75: 583-593. 10.1046/j.1471-4159.2000.0750583.x.
CAS
PubMed
Google Scholar
Albright CF, Dockens R, Olson RE, Meredith JE, Siemmon R, Lentz K, J W, Denton R, Pilcher G, Zaczek R: BMS-708163, a potent and selective g-secretase inhibitor, decreases CSF Ab at safe and tolerable doses in animals, and humans. International Conference on Alzheimer's Disease. 2008, Chicago: Alzheimer's Association, HT-01-05-
Google Scholar
Gillman KW, Starrett JE, Parker MF, Xie K, Bronson JJ, Marcin LR, McElhone KE, Bergstrom CP, Mate RA, Williams R, Meredith JE, Burton CR, Barten DM, Toyn JH, Roberts SB, Lentz KA, Houston JG, Zaczek R, Albright CF, Decicco CP, Macor JE, Olson RE: Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. ACS Medicinal Chemistry Letters. 2010, 1: 120-124. 10.1021/ml1000239.
PubMed Central
CAS
PubMed
Google Scholar
Tian G, Ghanekar SV, Aharony D, Shenvi AB, Jacobs RT, Liu X, Greenberg BD: The mechanism of gamma-secretase: multiple inhibitor binding sites for transition state analogs and small molecule inhibitors. J Biol Chem. 2003, 278: 28968-28975. 10.1074/jbc.M300905200.
CAS
PubMed
Google Scholar
Burton CR, Meredith JE, Barten DM, Goldstein ME, Krause CM, Kieras CJ, Sisk L, Iben LG, Polson C, Thompson MW, Lin XA, Corsa J, Fiedler T, Pierdomenico M, Cao Y, Roach AH, Cantone JL, Ford MJ, Drexler DM, Olson RE, Yang MG, Bergstrom CP, McElhone KE, Bronson JJ, Macor JE, Blat Y, Grafstrom RH, Stern AM, Seiffert DA, Zaczek R, et al: The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J Biol Chem. 2008, 283: 22992-23003. 10.1074/jbc.M804175200.
CAS
PubMed
Google Scholar
Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH, Pietrzik CU, Baumann K, Weggen S: Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J Biol Chem. 2007, 282: 24504-24513. 10.1074/jbc.M700618200.
CAS
PubMed
Google Scholar
Ikeuchi T, Dolios G, Kim SH, Wang R, Sisodia SS: Familial Alzheimer disease-linked presenilin 1 variants enhance production of both Abeta 1-40 and Abeta 1-42 peptides that are only partially sensitive to a potent aspartyl protease transition state inhibitor of "gamma-secretase". J Biol Chem. 2003, 278: 7010-7018. 10.1074/jbc.M209252200.
CAS
PubMed
Google Scholar
Xia W, Ostaszewski BL, Kimberly WT, Rahmati T, Moore CL, Wolfe MS, Selkoe DJ: FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex. Neurobiol Dis. 2000, 7: 673-681. 10.1006/nbdi.2000.0322.
CAS
PubMed
Google Scholar
Kreft A, Harrison B, Aschmies S, Atchison K, Casebier D, Cole DC, Diamantidis G, Ellingboe J, Hauze D, Hu Y, Huryn D, Jin M, Kubrak D, Lu P, Lundquist J, Mann C, Martone R, Moore W, Oganesian A, Porte A, Riddell DR, Sonnenberg-Reines J, Stock JR, Sun SC, Wagner E, Woller K, Xu Z, Zhou H, Steven Jacobsen J: Discovery of a novel series of Notch-sparing gamma-secretase inhibitors. Bioorg Med Chem Lett. 2008, 18: 4232-4236. 10.1016/j.bmcl.2008.05.064.
CAS
PubMed
Google Scholar
Mayer SC, Kreft AF, Harrison B, Abou-Gharbia M, Antane M, Aschmies S, Atchison K, Chlenov M, Cole DC, Comery T, Diamantidis G, Ellingboe J, Fan K, Galante R, Gonzales C, Ho DM, Hoke ME, Hu Y, Huryn D, Jain U, Jin M, Kremer K, Kubrak D, Lin M, Lu P, Magolda R, Martone R, Moore W, Oganesian A, Pangalos MN, et al: Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem. 2008, 51: 7348-7351. 10.1021/jm801252w.
CAS
PubMed
Google Scholar
Pu J, Kreft AF, Aschmies SH, Atchison KP, Berkowitz J, Caggiano TJ, Chlenov M, Diamantidis G, Harrison BL, Hu Y, Huryn D, Steven Jacobsen J, Jin M, Lipinski K, Lu P, Martone RL, Morris K, Sonnenberg-Reines J, Riddell DR, Sabalski J, Sun SC, Wagner E, Wang Y, Xu Z, Zhou H, Resnick L: Synthesis and structure-activity relationship of a novel series of heterocyclic sulfonamide gamma-secretase inhibitors. Bioorg Med Chem. 2009, 17: 4708-4717. 10.1016/j.bmc.2009.04.052.
CAS
PubMed
Google Scholar
Novel sulfonamide compounds and uses thereof. Patent PCT/US00//04560. [http://ip.com/patent/US6967196]
Parker MF, Barten DM, Bergstrom CP, Bronson JJ, Corsa JA, Deshpande MS, Felsenstein KM, Guss VL, Hansel SB, Johnson G, Keavy DJ, Lau WY, Mock J, Prasad CV, Polson CT, Sloan CP, Smith DW, Wallace OB, Wang HH, Williams A, Zheng M: N-(5-chloro-2-(hydroxymethyl)-N-alkyl-arylsulfonamides as gamma-secretase inhibitors. Bioorg Med Chem Lett. 2007, 17: 4432-4436. 10.1016/j.bmcl.2007.06.022.
CAS
PubMed
Google Scholar
Josien H, Bara T, Rajagopalan M, Asberom T, Clader JW, Favreau L, Greenlee WJ, Hyde LA, Nomeir AA, Parker EM, Pissarnitski DA, Song L, Wong GT, Zhang L, Zhang Q, Zhao Z: Small conformationally restricted piperidine N-arylsulfonamides as orally active gamma-secretase inhibitors. Bioorg Med Chem Lett. 2007, 17: 5330-5335. 10.1016/j.bmcl.2007.08.013.
CAS
PubMed
Google Scholar
Keown LE, Collins I, Cooper LC, Harrison T, Madin A, Mistry J, Reilly M, Shaimi M, Welch CJ, Clarke EE, Lewis HD, Wrigley JD, Best JD, Murray F, Shearman MS: Novel orally bioavailable gamma-secretase inhibitors with excellent in vivo activity. J Med Chem. 2009, 52: 3441-3444. 10.1021/jm900056p.
CAS
PubMed
Google Scholar
Sparey T, Beher D, Best J, Biba M, Castro JL, Clarke E, Hannam J, Harrison T, Lewis H, Madin A, Shearman M, Sohal B, Tsou N, Welch C, Wrigley J: Cyclic sulfamide gamma-secretase inhibitors. Bioorg Med Chem Lett. 2005, 15: 4212-4216. 10.1016/j.bmcl.2005.06.084.
CAS
PubMed
Google Scholar
Churcher I, Beher D, Best JD, Castro JL, Clarke EE, Gentry A, Harrison T, Hitzel L, Kay E, Kerrad S, Lewis HD, Morentin-Gutierrez P, Mortishire-Smith R, Oakley PJ, Reilly M, Shaw DE, Shearman MS, Teall MR, Williams S, Wrigley JD: 4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006, 16: 280-284. 10.1016/j.bmcl.2005.10.009.
CAS
PubMed
Google Scholar
Asberom T, Zhao Z, Bara TA, Clader JW, Greenlee WJ, Hyde LA, Josien HB, Li W, McPhail AT, Nomeir AA, Parker EM, Rajagopalan M, Song L, Wong GT, Zhang L, Zhang Q, Pissarnitski DA: Discovery of gamma-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease. Bioorg Med Chem Lett. 2007, 17: 511-516. 10.1016/j.bmcl.2006.10.011.
CAS
PubMed
Google Scholar
Gundersen E, Fan K, Haas K, Huryn D, Steven Jacobsen J, Kreft A, Martone R, Mayer S, Sonnenberg-Reines J, Sun SC, Zhou H: Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors. Bioorg Med Chem Lett. 2005, 15: 1891-1894. 10.1016/j.bmcl.2005.02.006.
CAS
PubMed
Google Scholar
Li H, Asberom T, Bara TA, Clader JW, Greenlee WJ, Josien HB, McBriar MD, Nomeir A, Pissarnitski DA, Rajagopalan M, Xu R, Zhao Z, Song L, Zhang L: Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors. Bioorg Med Chem Lett. 2007, 17: 6290-6294. 10.1016/j.bmcl.2007.09.006.
CAS
PubMed
Google Scholar
Pissarnitski DA, Asberom T, Bara TA, Buevich AV, Clader JW, Greenlee WJ, Guzik HS, Josien HB, Li W, McEwan M, McKittrick BA, Nechuta TL, Parker EM, Sinning L, Smith EM, Song L, Vaccaro HA, Voigt JH, Zhang L, Zhang Q, Zhao Z: 2,6-Disubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors. Bioorg Med Chem Lett. 2007, 17: 57-62. 10.1016/j.bmcl.2006.09.094.
CAS
PubMed
Google Scholar
Ye XM, Konradi AW, Smith J, Xu YZ, Dressen D, Garofalo AW, Marugg J, Sham HL, Truong A, Jagodzinski J, Pleiss M, Zhang H, Goldbach E, Sauer JM, Brigham E, Bova M, Basi GS: Discovery of a novel sulfonamide-pyrazolopiperidine series as potent and efficacious gamma-secretase inhibitors. Bioorg Med Chem Lett. 2010, 20: 2195-2199. 10.1016/j.bmcl.2010.02.039.
CAS
PubMed
Google Scholar
Walker ES, Martinez M, Brunkan AL, Goate A: Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J Neurochem. 2005, 92: 294-301. 10.1111/j.1471-4159.2004.02858.x.
CAS
PubMed
Google Scholar
Tolia A, Horre K, De Strooper B: Transmembrane domain 9 of presenilin determines the dynamic conformation of the catalytic site of gamma-secretase. J Biol Chem. 2008, 283: 19793-19803. 10.1074/jbc.M802461200.
CAS
PubMed
Google Scholar
Sato C, Morohashi Y, Tomita T, Iwatsubo T: Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines. J Neurosci. 2006, 26: 12081-12088. 10.1523/JNEUROSCI.3614-06.2006.
CAS
PubMed
Google Scholar
Tolia A, Chavez-Gutierrez L, De Strooper B: Contribution of presenilin transmembrane domains 6 and 7 to a water-containing cavity in the gamma-secretase complex. J Biol Chem. 2006, 281: 27633-27642. 10.1074/jbc.M604997200.
CAS
PubMed
Google Scholar
Bowers S, Probst GD, Truong AP, Hom RK, Konradi AW, Sham HL, Garofalo AW, Wong K, Goldbach E, Quinn KP, Sauer JM, Wallace W, Nguyen L, Hemphill SS, Bova MP, Basi GS: N-Bridged bicyclic sulfonamides as inhibitors of gamma-secretase. Bioorg Med Chem Lett. 2009, 19: 6952-6956. 10.1016/j.bmcl.2009.10.060.
CAS
PubMed
Google Scholar
Truong AP, Aubele DL, Probst GD, Neitzel ML, Semko CM, Bowers S, Dressen D, Hom RK, Konradi AW, Sham HL, Garofalo AW, Keim PS, Wu J, Dappen MS, Wong K, Goldbach E, Quinn KP, Sauer JM, Brigham EF, Wallace W, Nguyen L, Hemphill SS, Bova MP, Basi G: Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors. Bioorg Med Chem Lett. 2009, 19: 4920-4923. 10.1016/j.bmcl.2009.07.092.
CAS
PubMed
Google Scholar